Literature DB >> 17873061

Processing and function of CFTR-DeltaF508 are species-dependent.

Lynda S Ostedgaard1, Christopher S Rogers, Qian Dong, Christoph O Randak, Daniel W Vermeer, Tatiana Rokhlina, Philip H Karp, Michael J Welsh.   

Abstract

Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis. The most common mutation, a deletion of the phenylalanine at position 508 (DeltaF508), disrupts processing of the protein. Nearly all human CFTR-DeltaF508 is retained in the endoplasmic reticulum and degraded, preventing maturation to the plasma membrane. In addition, the F508 deletion reduces the activity of single CFTR channels. Human CFTR-DeltaF508 has been extensively studied to better understand its defects. Here, we adopted a cross-species comparative approach, examining human, pig, and mouse CFTR-DeltaF508. As with human CFTR-DeltaF508, the DeltaF508 mutation reduced the single-channel activity of the pig and mouse channels. However, the mutant pig and mouse proteins were at least partially processed like their wild-type counterparts. Moreover, pig and mouse CFTR-DeltaF508 partially restored transepithelial Cl(-) transport to CF airway epithelia. Our data, combined with earlier work, suggest that there is a gradient in the severity of the CFTR-DeltaF508 processing defect, with human more severe than pig or mouse. These findings may explain some previously puzzling observations in CF mice, they have important implications for evaluation of potential therapeutics, and they suggest new strategies for discovering the mechanisms that disrupt processing of human CFTR-DeltaF508.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17873061      PMCID: PMC1976592          DOI: 10.1073/pnas.0706974104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Pharmacologic approaches to correcting the basic defect in cystic fibrosis.

Authors:  Gergely L Lukacs; Peter R Durie
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

2.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

3.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

4.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

Review 5.  Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator.

Authors:  W R Skach
Journal:  Kidney Int       Date:  2000-03       Impact factor: 10.612

6.  Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs.

Authors:  Wei Wang; Ge Li; John Paul Clancy; Kevin L Kirk
Journal:  J Biol Chem       Date:  2005-04-27       Impact factor: 5.157

7.  In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant deltaF508 in murine nasal epithelium.

Authors:  T J Kelley; K Thomas; L J Milgram; M L Drumm
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

8.  Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects.

Authors:  Marie E Egan; Marilyn Pearson; Scott A Weiner; Vanathy Rajendran; Daniel Rubin; Judith Glöckner-Pagel; Susan Canny; Kai Du; Gergely L Lukacs; Michael J Caplan
Journal:  Science       Date:  2004-04-23       Impact factor: 47.728

9.  A mouse model for the delta F508 allele of cystic fibrosis.

Authors:  B G Zeiher; E Eichwald; J Zabner; J J Smith; A P Puga; P B McCray; M R Capecchi; M J Welsh; K R Thomas
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

10.  Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wild-type and mutant proteins.

Authors:  C L Ward; R R Kopito
Journal:  J Biol Chem       Date:  1994-10-14       Impact factor: 5.157

View more
  67 in total

1.  Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR.

Authors:  Andrei A Aleksandrov; Pradeep Kota; Liying Cui; Tim Jensen; Alexey E Alekseev; Santiago Reyes; Lihua He; Martina Gentzsch; Luba A Aleksandrov; Nikolay V Dokholyan; John R Riordan
Journal:  J Mol Biol       Date:  2012-03-08       Impact factor: 5.469

2.  Endogenous surface expression of ΔF508-CFTR mediates cAMP-stimulated Cl(-) current in CFTR(ΔF508/ΔF508) pig thyroid epithelial cells.

Authors:  Yonghai Li; Suhasini Ganta; Peying Fong
Journal:  Exp Physiol       Date:  2011-09-23       Impact factor: 2.969

3.  Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: protection by single suppressor mutations and inhibiting channel activity.

Authors:  Xuehong Liu; Nicolette O'Donnell; Allison Landstrom; William R Skach; David C Dawson
Journal:  Biochemistry       Date:  2012-06-15       Impact factor: 3.162

4.  Altered ion transport by thyroid epithelia from CFTR(-/-) pigs suggests mechanisms for hypothyroidism in cystic fibrosis.

Authors:  Hui Li; Suhasini Ganta; Peying Fong
Journal:  Exp Physiol       Date:  2010-08-20       Impact factor: 2.969

5.  Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule.

Authors:  Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard
Journal:  Br J Pharmacol       Date:  2018-02-22       Impact factor: 8.739

6.  Bcl-2 suppresses sarcoplasmic/endoplasmic reticulum Ca2+-ATPase expression in cystic fibrosis airways: role in oxidant-mediated cell death.

Authors:  Shama Ahmad; Aftab Ahmad; Elena S Dremina; Victor S Sharov; Xiaoling Guo; Tara N Jones; Joan E Loader; Jason R Tatreau; Anne-Laure Perraud; Christian Schöneich; Scott H Randell; Carl W White
Journal:  Am J Respir Crit Care Med       Date:  2009-02-06       Impact factor: 21.405

7.  Inhibition of acinar apoptosis occurs during acute pancreatitis in the human homologue DeltaF508 cystic fibrosis mouse.

Authors:  Matthew J DiMagno; Sae-Hong Lee; Chung Owyang; Shi-yi Zhou
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-03       Impact factor: 4.052

8.  Impact of the F508del mutation on ovine CFTR, a Cl- channel with enhanced conductance and ATP-dependent gating.

Authors:  Zhiwei Cai; Timea Palmai-Pallag; Pissared Khuituan; Michael J Mutolo; Clément Boinot; Beihui Liu; Toby S Scott-Ward; Isabelle Callebaut; Ann Harris; David N Sheppard
Journal:  J Physiol       Date:  2015-04-09       Impact factor: 5.182

9.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

10.  CFTR is a negative regulator of NFkappaB mediated innate immune response.

Authors:  Neeraj Vij; Steven Mazur; Pamela L Zeitlin
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.